Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial

Phase

Condition

Digestive System Neoplasms

Cancer

Liver Cancer

Treatment

TACE-HACI, plus atezolizumab-bevacizumab

Clinical Study ID

NCT05751343

2022-FXY-141

Ages 18-75
All Genders

Study Summary

Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for those patients is still unknown. This phase 2 clinical trial aims to investigate the objective response rate for unresectable advanced hepatocellular carcinoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

(a) patients were diagnozied with unresectable advanced-stage HCC,
(b) Child-Pugh A or B liver function;
(d) Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
(e) adequate hematologic blood counts (white blood cell count >3ⅹ109/L, absoluteneutrophil count >1.5ⅹ109/L, platelet count >10ⅹ109/L, hemoglobin concentration >85g/L);

Exclusion

Exclusion Criteria:

(a) severe underlying cardiac, pulmonary, or renal diseases;
(b) history of a second primary malignant tumor;
(c) contraindication to either atezolizumab and bevacizumab.

Study Design